We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Surgeons Transplant 3D-Bioprinted Ear Made of Patient’s Own Tissue

By HospiMedica International staff writers
Posted on 06 Jun 2022
Print article
Image: Actual image of 3D-printed AuriNovo “living” ear for reconstruction in Microtia patients (Photo courtesy of 3DBio Therapeutics)
Image: Actual image of 3D-printed AuriNovo “living” ear for reconstruction in Microtia patients (Photo courtesy of 3DBio Therapeutics)

Microtia is a rare congenital deformity where one or both outer ears are absent or underdeveloped and affects approximately 1,500 babies born in the US annually. In a transformational implant procedure, a team of pediatric ear reconstructive surgeons specializing in microtia has conducted a human ear reconstruction using an investigational, patient-matched, 3D-bioprinted living tissue ear implant.

3DBio Therapeutics (3DBio, Long Island City, NY, USA) and the Microtia-Congenital Ear Deformity Institute (San Antonio, TX, USA) performed the groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial evaluating the safety and preliminary efficacy of the AuriNovo implant, a living tissue ear implant for surgical reconstruction of the external ear in patients born with unilateral microtia. The Phase 1/2a clinical trial is a multicenter, single arm, prospective, open-label, staged study of the AuriNovo living tissue ear implant for surgical reconstruction of the external ear in patients born with unilateral microtia.

AuriNovo is a patient-specific, living tissue implant created using 3D-bioprinting technology for surgical reconstruction of the outer ear in people born with microtia Grades II-IV. It is designed to provide a treatment alternative to rib cartilage grafts and synthetic materials traditionally used to reconstruct the outer ear of microtia patients. Following 3D scanning of the opposite ear to specifically match the patient’s ear geometry, AuriNovo incorporates the patient’s own auricular cartilage cells into a 3D-bioprinted, living, full-sized ear construct designed to replace the patient’s microtia-affected ear. AuriNovo was granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for reconstruction of the outer ear in patients with microtia.

“My hope is that AuriNovo will one day become the standard-of-care replacing the current surgical methods for ear reconstruction requiring the harvesting of rib cartilage or the use of porous polyethylene (PPE) implants,” said Arturo Bonilla, M.D., a leading pediatric ear reconstructive surgeon specializing in microtia and the founder and director of the Microtia-Congenital Ear Deformity Institute. “The AuriNovo implant requires a less invasive surgical procedure than the use of rib cartilage for reconstruction. We also expect it to result in a more flexible ear than reconstruction with a PPE implant.”

“We believe that the microtia clinical trial can provide us not only with robust evidence about the value of this innovative product and the positive impact it can have for microtia patients, but also demonstrate the potential for the technology to provide living tissue implants in other therapeutic areas in the future,” said Daniel Cohen, Ph.D., 3DBio Chief Executive Officer and Co-founder. “Our initial indications focus on cartilage in the reconstructive and orthopedic fields including treating complex nasal defects and spinal degeneration. We look forward to leveraging our platform to solve other high impact, unmet medical needs like lumpectomy reconstruction and eventually expand to organs.”

Related Links:
3DBio Therapeutics 
Microtia-Congenital Ear Deformity Institute 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Bilirubin Lamp
Bilibluelight

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.